Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

An Oral Disease-Modifying Drug for Relapsing-Remitting Multiple Sclerosis Would Earn High Patient Shares in Both Europe and the

Posted Nov 17 2009 10:20pm
PR Newswire

An Oral Disease-Modifying Drug for Relapsing-Remitting Multiple Sclerosis Would Earn High Patient Shares in Both Europe and the United States

Website

WALTHAM, Mass., Feb. 4 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, f inds that an oral disease-modifying therapy for relapsing-remitting multiple sclerosis would earn a 50 percent patient share in Europe and a 40 percent patient share in the United States, according to surveyed U.S. and European neurologists.

» Read More

.
Posting comments can be beneficial to others and it allows you to express yourself.
If you have a statement or question pertaining to this article, this is the place to leave it.
Click the link below the article that reads: Post Comments. - Thank You
============================================
Post a comment
Write a comment:

Related Searches